Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Linperlisib in Combination with CHOP for Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from the Phase 1b/2 Linch Study

Qingqing Cai, Yi Xia, Huiqiang Huang, Ying Zhao, Fan Yang, Wenning Xu, Hongyan Tong, Chunmei Yang, Xiaojie Fang, Man Nie, Yu Fang, Gao Yan, Xuanye Zhang, Rong Tao, Xiuhua Sun, Xueyi Pan, Tao Wu, Yuchen Zhang, Jun Cai

Blood (2024) 144 (Supplement 1): 6407.

https://doi.org/10.1182/blood-2024-206564

Published: 2024

Journal Articles

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Jie Jin, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen, Qingqing Cai

Blood (2024) 144 (Supplement 1): 6368.

https://doi.org/10.1182/blood-2024-211891

Published: 2024

Journal Articles

Preliminary Results from a Phase II Study of Chidamide in Combination with CHOP in Previously Untreated Peripheral T-Cell Lymphoma with T Follicular Helper Phenotype (SWIFT study)

Qingqing Cai, Yi Xia, Dongfeng Zeng, Xi Li, Xiaojie Fang, Man Nie, Xiaopeng Tian, Lirong Li, Yingxian Liu

Blood (2024) 144 (Supplement 1): 7779.

https://doi.org/10.1182/blood-2024-206953

Published: 2024

Journal Articles

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Blood (2024) 144 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2024-202823

Published: 2024

Journal Articles

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Blood (2024) 144 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2024-194572

Published: 2024

Journal Articles

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Ranjana H. Advani, Michael J. Dickinson, Christopher P. Fox, Brad Kahl, Alex F. Herrera, Georg Lenz, Yuqin Song, Rong Tao, Qingqing Cai, Tae Min Kim, Michelle Doral, Derrick Kaufman, Leonardo Roque Pereira, Aurelien Berthier, Franck Morschhauser

Blood (2024) 144 (Supplement 1): 1718.1.

https://doi.org/10.1182/blood-2024-194000

Published: 2024

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Blood (2024) 144 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2024-209224

Published: 2024

Journal Articles

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2024-194561

Published: 2024

Journal Articles

TQB2223 in Combination with Penpulimab in Patients with Relapsed or Refractory Lymphoma: Primary Analysis of an Open-Label Phase I Study

Qingqing Cai, Yi Xia, Xiaojie Fang, Man Nie, Qihua Zou, Jun Cai, Yuchen Zhang, Qiuyi Yang, Dawei Ding, Wen Wang, Xunqiang Wang

Blood (2024) 144 (Supplement 1): 3047.

https://doi.org/10.1182/blood-2024-203156

Published: 2024

Journal Articles

A Phase II Study of Zanubrutinib-Based Induction and Maintenance Therapy in Young and Fit Patients with Untreated Mantle Cell Lymphoma (BRIDGE): An Updated Analysis with Long-Term Follow up

Gao Yan, Qingqing Cai, Zhiming Li, Xiaoxiao Wang, Yi Xia, Xuanye Zhang, He Huang, Bin Bai, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 6147.

https://doi.org/10.1182/blood-2023-181619

Published: 2023

Journal Articles

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Blood (2023) 142 (Supplement 1): 6638.

https://doi.org/10.1182/blood-2023-183100

Published: 2023

Journal Articles

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2023) 142 (Supplement 1): 4469.

https://doi.org/10.1182/blood-2023-173645

Published: 2023

Journal Articles

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Yuqin Song, Qingqing Cai, Qingyuan Zhang, Xiuhua Sun, Haiyan Yang, Zhihua Yao, Liqun Zou, Liling Zhang, Junning Cao, Tingyu Wang, Lanfang Li, Yao Liu, Hongmei Jing, Sujun Gao, Kaiyang Ding, Bingshan Liu, Jun Zhao, Jun Zhu

Blood (2023) 142 (Supplement 1): 6234.

https://doi.org/10.1182/blood-2023-180413

Published: 2023

Journal Articles

A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Jun Zhu, Yuqin Song, Ye Guo, Keshu Zhou, Wenyu Li, Yu Yang, Qingqing Cai, Zhao Wang, Haiyan Yang

Blood (2023) 142 (Supplement 1): 3089.

https://doi.org/10.1182/blood-2023-189675

Published: 2023

Journal Articles

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3033.

https://doi.org/10.1182/blood-2023-180694

Published: 2023

Journal Articles

Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)

Jie Jin, Qingqing Cai, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen

Blood (2023) 142 (Supplement 1): 4430.

https://doi.org/10.1182/blood-2023-185543

Published: 2023

Journal Articles

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

Blood (2023) 142 (Supplement 1): 4400.

https://doi.org/10.1182/blood-2023-180485

Published: 2023

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Clinical Trial

Qingqing Cai, Yi Xia, Liang Wang, Huiqiang Huang, Jinni Wang, Jun Cai, Xiaopeng Tian

Blood (2023) 142 (Supplement 1): 4470.

https://doi.org/10.1182/blood-2023-188430

Published: 2023

Journal Articles

Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)

Blood (2023) 142 (Supplement 1): 305.

https://doi.org/10.1182/blood-2023-172962

Published: 2023

Journal Articles

Genetic and Prognostic Analysis in Blastoid and Pleomorphic Mantle Cell Lymphoma: A Multicenter Analysis in China

Ping Yang, Shuozi Liu, Chunyuan Li, Weilong Zhang, Jing Wang, Yingtong Chen, Sen Li, Cuiling Liu, Hui Liu, Qingqing Cai, Wei Zhang, Hongmei Jing

Blood (2022) 140 (Supplement 1): 11907–11908.

https://doi.org/10.1182/blood-2022-165107

Published: 2022

NARROW

Linperlisib in Combination with CHOP for Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from the Phase 1b/2 Linch Study

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Preliminary Results from a Phase II Study of Chidamide in Combination with CHOP in Previously Untreated Peripheral T-Cell Lymphoma with T Follicular Helper Phenotype (SWIFT study)

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Rocbrutinib, a New-Generation BTK Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non-GCB Diffuse Large B Cell Lymphoma

TQB2223 in Combination with Penpulimab in Patients with Relapsed or Refractory Lymphoma: Primary Analysis of an Open-Label Phase I Study

A Phase II Study of Zanubrutinib-Based Induction and Maintenance Therapy in Young and Fit Patients with Untreated Mantle Cell Lymphoma (BRIDGE): An Updated Analysis with Long-Term Follow up

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Search Study：XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Safety and Efficacy Results from the Phase I Study of a Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)

A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Clinical Trial

Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)

Genetic and Prognostic Analysis in Blastoid and Pleomorphic Mantle Cell Lymphoma: A Multicenter Analysis in China

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only